Switch theme
Sign up to access all valuation multiples
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.
2004
56
LTM Revenue $42.2M
LTM EBITDA -$9.6M
$204M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Santhera Pharma has a last 12-month revenue of $42.2M and a last 12-month EBITDA of -$9.6M.
In the most recent fiscal year, Santhera Pharma achieved revenue of $117M and an EBITDA of $89.5M.
Santhera Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Santhera Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $117M | $36.1M | XXX | XXX | XXX |
| Gross Profit | -$6.1M | $4.4M | XXX | XXX | XXX |
| Gross Margin | -5% | 12% | XXX | XXX | XXX |
| EBITDA | $89.5M | -$16.8M | XXX | XXX | XXX |
| EBITDA Margin | 77% | -47% | XXX | XXX | XXX |
| Net Profit | -$62.8M | -$80.4M | XXX | XXX | XXX |
| Net Margin | -54% | -222% | XXX | XXX | XXX |
| Net Debt | $22.6M | $47.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Santhera Pharma's stock price is CHF 14 (or $15).
Santhera Pharma has current market cap of CHF 171M (or $193M), and EV of CHF 181M (or $204M).
See Santhera Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $204M | $193M | XXX | XXX | XXX | XXX | $-2.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Santhera Pharma has market cap of $193M and EV of $204M.
Santhera Pharma's trades at 4.8x LTM EV/Revenue multiple, and -21.4x LTM EBITDA.
Analysts estimate Santhera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Santhera Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $204M | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | -12.1x | XXX | XXX | XXX |
| P/E | -6.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSanthera Pharma's NTM/LTM revenue growth is 61%
Santhera Pharma's revenue per employee for the last fiscal year averaged $2.1M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Santhera Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Santhera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Santhera Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -69% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -47% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -119% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 14% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Santhera Pharma acquired XXX companies to date.
Last acquisition by Santhera Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Santhera Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Santhera Pharma founded? | Santhera Pharma was founded in 2004. |
| Where is Santhera Pharma headquartered? | Santhera Pharma is headquartered in Switzerland. |
| How many employees does Santhera Pharma have? | As of today, Santhera Pharma has 56 employees. |
| Is Santhera Pharma publicy listed? | Yes, Santhera Pharma is a public company listed on SWX. |
| What is the stock symbol of Santhera Pharma? | Santhera Pharma trades under SANN ticker. |
| When did Santhera Pharma go public? | Santhera Pharma went public in 2006. |
| Who are competitors of Santhera Pharma? | Similar companies to Santhera Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Santhera Pharma? | Santhera Pharma's current market cap is $193M |
| What is the current revenue of Santhera Pharma? | Santhera Pharma's last 12-month revenue is $42.2M. |
| What is the current EBITDA of Santhera Pharma? | Santhera Pharma's last 12-month EBITDA is -$9.6M. |
| What is the current EV/Revenue multiple of Santhera Pharma? | Current revenue multiple of Santhera Pharma is 4.8x. |
| What is the current EV/EBITDA multiple of Santhera Pharma? | Current EBITDA multiple of Santhera Pharma is -21.4x. |
| What is the current revenue growth of Santhera Pharma? | Santhera Pharma revenue growth between 2023 and 2024 was -69%. |
| Is Santhera Pharma profitable? | Yes, Santhera Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
